Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity

Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442 Kim, 2018, Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015, Cancer, 124, 2588, 10.1002/cncr.31373 Iñarrairaegui, 2018, Immunotherapy of hepatocellular carcinoma: facts and hopes, Clin. Cancer Res., 24, 1518, 10.1158/1078-0432.CCR-17-0289 Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med., 359, 378, 10.1056/NEJMoa0708857 Ambros, 2004, The functions of animal microRNAs, Nature, 431, 350, 10.1038/nature02871 Bader, 2010, The promise of microRNA replacement therapy, Cancer Res., 70, 7027, 10.1158/0008-5472.CAN-10-2010 Klingenberg, 2017, Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets, J. Hepatol., 67, 603, 10.1016/j.jhep.2017.04.009 Kota, 2009, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, Cell, 137, 1005, 10.1016/j.cell.2009.04.021 Rupaimoole, 2017, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat. Rev. Drug Discov., 16, 203, 10.1038/nrd.2016.246 Yu, 2016, MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy, Drug Metab. Dispos., 44, 308, 10.1124/dmd.115.067470 Xie, 2018, Potential regulatory roles of microRNAs and long noncoding RNAs in anticancer therapies, Mol. Ther. Nucleic Acids, 13, 233, 10.1016/j.omtn.2018.08.019 Callegari, 2018, miR-199a-3p modulates MTOR and PAK4 pathways and inhibits tumor growth in a hepatocellular carcinoma transgenic mouse model, Mol. Ther. Nucleic Acids, 11, 485, 10.1016/j.omtn.2018.04.002 Fu, 2012, Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells, Mol. Ther., 20, 339, 10.1038/mt.2011.265 Sandbothe, 2017, The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4, J. Hepatol., 66, 1012, 10.1016/j.jhep.2017.01.004 Wu, 2017, MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice, Hepatology, 66, 1952, 10.1002/hep.29374 Zhang, 2015, Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis, Hepatology, 61, 561, 10.1002/hep.27491 Lu, 2013, MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3, Biochem. Biophys. Res. Commun., 441, 873, 10.1016/j.bbrc.2013.10.157 Yu, A.M., Jian, C., Yu, A.H., and Tu, M.J. RNA therapy: are we using the right molecules? Pharmacol. Ther. Published online December 4, 2018. https://doi.org/10.1016/j.pharmthera.2018.11.011. Chen, 2015, A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications, Nucleic Acids Res., 43, 3857, 10.1093/nar/gkv228 Ho, 2018, Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy, J. Pharmacol. Exp. Ther., 365, 494, 10.1124/jpet.118.247775 Ho, 2016, Bioengineering of noncoding RNAs for research agents and therapeutics, Wiley Interdiscip. Rev. RNA, 7, 186, 10.1002/wrna.1324 Jian, 2017, Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models, Oncotarget, 8, 30742, 10.18632/oncotarget.16372 Li, 2018, Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells, Drug Metab. Dispos., 46, 2, 10.1124/dmd.117.078741 Wang, 2015, Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization, J. Pharmacol. Exp. Ther., 354, 131, 10.1124/jpet.115.225631 Tu, 2019, Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models, Cancer Lett., 442, 82, 10.1016/j.canlet.2018.10.038 Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J. Control. Release, 114, 100, 10.1016/j.jconrel.2006.04.014 Rezaee, 2016, Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems, J. Control. Release, 236, 1, 10.1016/j.jconrel.2016.06.023 Ewe, 2017, Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo, Nanomedicine (Lond.), 13, 209, 10.1016/j.nano.2016.08.005 Ewe, 2014, Storage stability of optimal liposome-polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery, Acta Biomater., 10, 2663, 10.1016/j.actbio.2014.02.037 Schäfer, 2010, Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery, Biomaterials, 31, 6892, 10.1016/j.biomaterials.2010.05.043 Zhang, 2018, Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo, Int. J. Pharm., 547, 537, 10.1016/j.ijpharm.2018.06.026 Nam, 2011, Molecular basis for interaction of let-7 microRNAs with Lin28, Cell, 147, 1080, 10.1016/j.cell.2011.10.020 Liao, 2016, let-7 modulates chromatin configuration and target gene repression through regulation of the ARID3B complex, Cell Rep., 14, 520, 10.1016/j.celrep.2015.12.064 Shimizu, 2010, The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma, J. Hepatol., 52, 698, 10.1016/j.jhep.2009.12.024 Sampson, 2007, MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells, Cancer Res., 67, 9762, 10.1158/0008-5472.CAN-07-2462 Lee, 2007, The tumor suppressor microRNA let-7 represses the HMGA2 oncogene, Genes Dev., 21, 1025, 10.1101/gad.1540407 Mayr, 2007, Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation, Science, 315, 1576, 10.1126/science.1137999 Gramantieri, 2007, Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma, Cancer Res., 67, 6092, 10.1158/0008-5472.CAN-06-4607 Hou, 2011, Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma, Cancer Cell, 19, 232, 10.1016/j.ccr.2011.01.001 Nakao, 2014, Antitumor function of microRNA-122 against hepatocellular carcinoma, J. Gastroenterol., 49, 589, 10.1007/s00535-014-0932-4 Robbins, 2009, siRNA and innate immunity, Oligonucleotides, 19, 89, 10.1089/oli.2009.0180 Yu, 2012, Recognition of nucleic acid ligands by toll-like receptors 7/8: importance of chemical modification, Curr. Med. Chem., 19, 1365, 10.2174/092986712799462603 Li, 2015, Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity, Drug Metab. Dispos., 43, 1129, 10.1124/dmd.115.064493 Guo, 2006, Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma, Gene, 384, 51, 10.1016/j.gene.2006.07.011 McDaniel, 2016, Lin28 and let-7: roles and regulation in liver diseases, Am. J. Physiol. Gastrointest. Liver Physiol., 310, G757, 10.1152/ajpgi.00080.2016 Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science, 318, 1917, 10.1126/science.1151526 Reinhart, 2000, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans, Nature, 403, 901, 10.1038/35002607 Viswanathan, 2010, Lin28: a microRNA regulator with a macro role, Cell, 140, 445, 10.1016/j.cell.2010.02.007 Kim, 2016, Recent progress in development of siRNA delivery vehicles for cancer therapy, Adv. Drug Deliv. Rev., 104, 61, 10.1016/j.addr.2016.06.011 Sullenger, 2016, From the RNA world to the clinic, Science, 352, 1417, 10.1126/science.aad8709 Xue, 2015, Lipid-based nanocarriers for RNA delivery, Curr. Pharm. Des., 21, 3140, 10.2174/1381612821666150531164540 Xia, 2016, Effect of surface properties on liposomal siRNA delivery, Biomaterials, 79, 56, 10.1016/j.biomaterials.2015.11.056 Zhao, 2015, Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth, Biochem. Pharmacol., 98, 602, 10.1016/j.bcp.2015.10.015 Carr, 2014, Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype, Semin. Oncol., 41, 252, 10.1053/j.seminoncol.2014.03.006